Cagrilintide: The Amylin Half of CagriSema
A weekly amylin receptor agonist with a C20 fatty diacid linker. Pairs with semaglutide as CagriSema, producing the highest weight loss of any GLP-1-class therapy submitted to the FDA so far.
How It Works
Cagrilintide binds the amylin receptor (AMY-R) and the related calcitonin receptor. Amylin is co-secreted with insulin from pancreatic β-cells and signals satiety to the brainstem.
Amylin pathway slows stomach emptying via vagal signaling — similar effect to GLP-1, but through a different receptor. Combining the two stacks the satiety signal.
Acts on amylin receptors in the area postrema and hypothalamus to suppress appetite. The non-GLP-1 pathway is why CagriSema beats semaglutide alone — it pulls a different lever.
Same lipidation strategy as semaglutide and tirzepatide. Albumin binding extends half-life to ~7 days, enabling once-weekly subcutaneous injection.
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- 20.4% mean weight loss at 68 weeks with CagriSema in non-diabetics (REDEFINE 1, NEJM 2025) — slightly above tirzepatide.
- 13.7% mean weight loss in T2D patients (REDEFINE 2) — roughly double placebo.
- Cagrilintide alone produces ~11.5% loss — competitive with semaglutide monotherapy.
- Novo Nordisk submitted CagriSema to FDA in December 2025; potential 2026 approval.
- Amylin and GLP-1 pathways are pharmacologically distinct, which is why combining them adds rather than overlaps benefit.
- GI adverse-event rate ~80% in trials — driven mostly by the semaglutide component.
- Long-term (>2 yr) durability of the additive amylin+GLP-1 effect.
- Whether cagrilintide monotherapy will ever be marketed separately from semaglutide.
- Head-to-head CagriSema vs retatrutide outcomes (no direct comparison trial yet).
- Optimal dose ratio when neither component is at its maximum.
- Cardiovascular outcomes trial data (REDEFINE-CVOT ongoing).
Frequently Asked Questions
What is cagrilintide?
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. It is a 37-amino-acid peptide with a C20 fatty diacid linker giving it a 7-day half-life for once-weekly subcutaneous injection. Cagrilintide is rarely used alone — its main role is as the amylin half of CagriSema, paired with semaglutide.
What is CagriSema?
CagriSema is the fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) in a single weekly injection. In the REDEFINE 1 trial, it produced 20.4% mean weight loss at 68 weeks — slightly more than tirzepatide and dramatically more than semaglutide alone (14.9%).
How does cagrilintide differ from GLP-1 drugs?
Cagrilintide acts on amylin receptors, not GLP-1 receptors. Amylin is a separate satiety hormone co-secreted with insulin from pancreatic β-cells. The two pathways are pharmacologically independent, which is why combining them adds weight-loss benefit rather than just doubling the dose of one mechanism.
When will CagriSema be FDA-approved?
Novo Nordisk submitted CagriSema to the FDA for chronic weight management in December 2025, supported by the REDEFINE 1 and REDEFINE 2 Phase 3 trials. Standard FDA review is ~10 months, putting potential approval in late 2026. No firm date is published yet.
How does CagriSema compare to retatrutide?
No head-to-head trial exists. CagriSema produced 20.4% loss at 68 weeks in REDEFINE 1; retatrutide produced 22.8% at 48 weeks in TRIUMPH-1 (different durations make direct comparison imperfect). Both meaningfully exceed tirzepatide (~21% in SURMOUNT-1 at 72 weeks).
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.
Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
Information on this page is for research and educational use only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any decision related to a peptide, drug, or supplement.
HighPeptides may earn an affiliate commission from qualifying purchases via Amazon and other partner links on this page, at no extra cost to you.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.